

Melanoma Maligno

Alfainterferon 2b em altas doses

Indução: 20 MUI/m²/dia IV durante 20 min, 5 vezes por semana, durante 4 semanas

Consolidação/Manutenção: 10 MUI/m²/dia SC, 3 vezes por semana durante 48 semanas. Ref. (1)

Dacarbazina (DTIC)*

Dacarbazina: 250 mg/m²/dia IV durante 30-60 minutos D1 ao D5 a cada 21 ou 28 dias

OU

Dacarbazina: 1000 mg/m²/dia IV durante 30 minutos D1 a cada 21 dias

Ref. (2)

Alfainterferon 2b

Alfainterferon 2b: 20 MUI/m²/dia IM, 3 vezes por semana durante 12 semanas. Ref. (3)

Interleucina-2 (IL-2) em altas doses

Interleucina-2: 720.000 UI/kg IV durante 15 minutos a cada 8h - máximo 12 a 15 doses por ciclo (do D1 ao D4 ou do D1 ao D5).

A primeira dose do segundo curso de IL-2 deve ser administrada 14 dias após a primeira dose do primeiro curso.

a cada 6 a 12 semanas

Ref. (4)

Temozolomida

Temozolomida: 200 mg/m²/dia VO D1-5.

a cada 28 dias

Ref. (5)

Fotemustina

Indução: 100mg/m² IV durante 60 min D1, D8 e D15, com intervalo de 05 semanas.

Manutenção: 100mg/m² IV durante 60 min D1 a cada 03 semanas.

Ref. (6)

Dacarbazina (DTIC) + Carmustina (BCNU) + Cisplatina

Dacarbazina: 220 mg/m²/dia IV em 30-60 min D1 ao D3 a cada 21 dias

Cisplatina: 25 mg/m²/dia IV em 30-45 min D1 ao D3 a cada 21 dias

Carmustina: 150 mg/m² IV durante 2 a 3 horas D1 a cada 42 dias.

Ref. (7)

Paclitaxel + Carboplatina

Paclitaxel: 100 mg/m² IV durante 1 hora

Carboplatina: AUC 2 IV em 30 min D1, D8 e D15 a cada 28 dias.

OU

Paclitaxel: 175-200 mg/m² IV durante 3 horas

Carboplatina: AUC 5 IV em 60min D1 a cada 21 dias.

Ref. (8)

Bioquimioterapia

Cisplatina + Vinblastina + Dacarbazina + IL-2 + IFN α 2b

Cisplatina: 20mg/m²/dia IV em 30 min D1 ao D4

Vinblastina: 1,2mg/m²/dia IV pulso D1 ao D4

Dacarbazina: 800 mg/m²/dia IV em 1 hora D1 (administrar 1 hora após Vinblastina)

IL-2: 9 MUI/m² IV em 24h infusão contínua D1-4 (total de 96h)
Alfainterferon 2b: 5 MUI/m² SC D1 ao D5, D8, D10 e D12
Filgrastima: 5mcg/Kg/d SC D7 ao D16
a cada 21 dias, com o máximo de 4 ciclos. Ref. (9)

Paclitaxel

Paclitaxel: 90 mg/m² IV(80min) D1, D5 e D9 a cada 21 dias
Ref. (10)

CVD

Cisplatina: 20mg/m²/dia IV D2 a D5
Vinblastina: 1,6mg/m²/dia IV D1 a D5
Dacarbazina: 800 mg/m² IV D1 a cada 21 dias
Ref. (11)

Regime Dartmouth*

Carmustina: 150 mg/m² IV D1
Cisplatina: 25 mg/m² IV D1 a D3
Dacarbazina: 220 mg/m² IV D1 a D3 a cada 21 dias

*Além dos quimioterápicos, o regime inclui também tamoxifeno, 10 mg, 2 vezes ao dia, com início 1 semana antes da quimioterapia e tomado de forma contínua.

Ref. (12)

1. Kirkwood JM, *et al.* Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Trial EST 1684. *J Clin Oncol* 1996;14:7-17.
Kirkwood JM, *et al.* High-dose Interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup Trial E1694/S9512/C509801. *J Clin Oncol* 2001;19:2370-80.
Kirkwood JM, *et al.* A pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High – Dose Interferon for Melanoma. *Clin Cancer Res* 2004; 10:1670-1677.

- 2.** Middleton MR, *et al.* Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. *J Clin Oncol* 2000; 18: 158–66.

Avril, MF *et al.* Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. *J Clin Oncol* 2004; 22:1118-25.

Chapman PB, *et al.* Phase III multicentric randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. *J Clin Oncol* 1999; 17:2745-51.

Eigentler, TK *et al.* Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. *Lancet Oncol* 2003;4:748-59.
- 3.** Kirkwood JM, *et al.* Advances in the diagnosis and treatment of malignant melanoma. *Semin Oncol* 1997;24 (suppl 4): 1-48.
- 4.** Smith, FO *et al.* Treatment of metastatic melanoma using Interleukin-2 alone or in conjunction with vaccines. *Clin Cancer Res* 2008;14:5610-18.

Atkins, MB *et al.* High-Dose recombinant Interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol* 1999; 17: 2105-16.

Schwartzentruber, DJ. Guidelines for the safe administration of high-dose interleukin-2. *J Immunother* 2001; 24:287-93.
- 5.** Middleton MR, *et al.* Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. *J Clin Oncol* 2000;18:158-166.
- 6.** Avril, MF *et al.* Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. *J Clin Oncol* 2004; 22:1118-1125.
- 7.** Chapman PB, *et al.* Phase III multicentric randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. *J Clin Oncol* 1999; 17:2745-51.

Creagen ET, *et al.* Phase III clinical trial of the combination of

cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. *J Clin Oncol* 1999;17:1884-1890.

8. Rao, RD *et al.* Combination of paclitaxel and carboplatin as second-Line therapy for patients with metastatic melanoma. *Cancer* 2006;106:375-82.
9. Atkins,MB *et al.* Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. *J Clin Oncol* 2008; 26:5748-5754.
10. Bedikian AY, *et al.* Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma *Melanoma Res* 2004;14:63-6.
11. Legha SS, *et al.* A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma *Cancer* 1989;64:2024-9.
12. Chapman PS, *et al.* Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma. *J Clin Oncol* 1999; 17:2745-51.